kidney cancer imaging. TLX250-CDx is an investigational PET3 drug product for the non-invasive diagnosis and characterization of clear cell renal cell carcinoma (ccRCC), the most common and ...

If approved, it would be the first targeted PET imaging agent for kidney cancer available in the U.S., highlighting Telix’s expanding presence in the urology imaging market. Investors might find ...

The MIRAGE trial highlighted how MRI-guided stereotactic body radiotherapy with tight margins can reduce the long-term side ...

Comparing the change in estimated glomerular filtration rate (eGFR) before and after COVID, individuals had a mean eGFR decline that was 5.0 mL/min/1.73 m 2 faster after infection in hospitalized ...

Telix CEO Chris Behrenbruch has been awarded a 68% base pay rise ahead of expected FDA approval of its kidney cancer diagnosis tool. To enable this Telix has filed a biologics licensing ...

Fluid collection is a common complication after kidney transplantation. Causes of fluid collection are: lymphocele, urine leak, hematoma, and seroma. Fluid collections can be asymptomatic ...

Dorfman was diagnosed with “one large and one small hematoma” that was causing her discomfort. According to the Cleveland Clinic, a hematoma is defined as a closed wound, where blood collects ...

If approved, TLX250-CDx will be the first and only targeted PET agent specifically for kidney cancer to be commercially available in the U.S., further building on Telix’s successful urology imaging ...

Telix has filed for FDA approval of its next key nuclear imaging tool Dimerix reaches a key recruitment milestone in its phase III kidney disease trial Proteomics shares bound 20% after endometriosis ...

In chronic kidney disease, the kidneys are unable to filter excess water and waste out of your blood as they should. Early detection of kidney disease combined with dietary and lifestyle changes can ...